Thursday, February 06, 2025 1:13:18 PM
Why did Minister Andrew Gwynne just now zero in specifically on brain
tumors as an area where things have not progressed at all? If he had
received information that DCVax-L is useless or has limited potential,
what would have been the purpose of mentioning now the long standing lack
of progress in the treatment of brain tumors? I also believe that the Minister
would not have made the statement if he had been of the opinion that
DCvax-L's efficacy is very limited?
Also, since we, the MB posters have information about the capacity of DCVax-L to be
potentiated ( e.g. polyICLC, Keytruda), does anyone believe that Minister Andrew
Gwynne knows less than we do?
Bottom line: I suspect that the Minister's statement at this time is an effort
to make the public aware of the importance of an effective brain tumor treatment
that will soon be introduced to the UK market.
tumors as an area where things have not progressed at all? If he had
received information that DCVax-L is useless or has limited potential,
what would have been the purpose of mentioning now the long standing lack
of progress in the treatment of brain tumors? I also believe that the Minister
would not have made the statement if he had been of the opinion that
DCvax-L's efficacy is very limited?
Also, since we, the MB posters have information about the capacity of DCVax-L to be
potentiated ( e.g. polyICLC, Keytruda), does anyone believe that Minister Andrew
Gwynne knows less than we do?
Bottom line: I suspect that the Minister's statement at this time is an effort
to make the public aware of the importance of an effective brain tumor treatment
that will soon be introduced to the UK market.
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
